Abstract
The blood-brain barrier significantly impedes treatment of central nervous system disorders by preventing drug entry into the brain. Several strategies have been developed to overcome this problem, but progress has been hampered due to a lack of efficacious drug delivery systems (DDS). Now, owing to DDS, therapeutic compounds can be transported to the site of action and accumulate there. This modern approach allows one to decrease the required dose of drug and, therefore, minimize toxicity and side effects. Also, treatment efficiency is increased. Highly organized nanostructures made of biological, polymeric or carbon-based materials are promising carriers in drug delivery to the brain, due to their unique and easily tailorable properties. The drug can be either attached to or entrapped in a carrier. To achieve greater site specificity and selectivity, DDS can be also modified with suitable ligands, providing identification of the molecular site of action. This review illustrates recent advances in using highly-organized structures: dendrimers, fullerenes, liposomes, micelles, nanogels, nanoparticles and nanotubes for this purpose. We also discuss advantages and limitations of each system.
Keywords: Blood brain barrier, brain drug delivery, drug delivery systems, nanocarriers, nanoparticles, nanotechnology.
CNS & Neurological Disorders - Drug Targets
Title:Highly Organized Nanostructures for Brain Drug Delivery - New Hope or Just a Fad?
Volume: 12 Issue: 8
Author(s): K. Labuzek, K. Gorki, H. Jaroszek, K. Jarzabek, B. Gabryel and B. Okopien
Affiliation:
Keywords: Blood brain barrier, brain drug delivery, drug delivery systems, nanocarriers, nanoparticles, nanotechnology.
Abstract: The blood-brain barrier significantly impedes treatment of central nervous system disorders by preventing drug entry into the brain. Several strategies have been developed to overcome this problem, but progress has been hampered due to a lack of efficacious drug delivery systems (DDS). Now, owing to DDS, therapeutic compounds can be transported to the site of action and accumulate there. This modern approach allows one to decrease the required dose of drug and, therefore, minimize toxicity and side effects. Also, treatment efficiency is increased. Highly organized nanostructures made of biological, polymeric or carbon-based materials are promising carriers in drug delivery to the brain, due to their unique and easily tailorable properties. The drug can be either attached to or entrapped in a carrier. To achieve greater site specificity and selectivity, DDS can be also modified with suitable ligands, providing identification of the molecular site of action. This review illustrates recent advances in using highly-organized structures: dendrimers, fullerenes, liposomes, micelles, nanogels, nanoparticles and nanotubes for this purpose. We also discuss advantages and limitations of each system.
Export Options
About this article
Cite this article as:
Labuzek K., Gorki K., Jaroszek H., Jarzabek K., Gabryel B. and Okopien B., Highly Organized Nanostructures for Brain Drug Delivery - New Hope or Just a Fad?, CNS & Neurological Disorders - Drug Targets 2013; 12 (8) . https://dx.doi.org/10.2174/18715273113129990109
DOI https://dx.doi.org/10.2174/18715273113129990109 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Role of Resveratrol in Modulating microRNAs in Human Diseases: From Cancer to Inflammatory Disorder
Current Medicinal Chemistry Omega-3 Polyunsaturated Fatty Acids and Cancer
Anti-Cancer Agents in Medicinal Chemistry An Emerging Strategy for Cancer Treatment Targeting Aberrant Glycogen Synthase Kinase 3β
Anti-Cancer Agents in Medicinal Chemistry Enhanced Free Radical Status of Cancer Cells Success and Failure of Prooxidant/Antioxidant Treatment
Current Signal Transduction Therapy Kinin Receptors in Vascular Biology and Pathology
Current Vascular Pharmacology Anticancer Agent Ukrain and Bortezomib Combination is Synergistic in 4T1 Breast Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Molecular and Cellular Regulators of Cancer Angiogenesis
Current Cancer Drug Targets Recent Advances in the Structure-Based and Ligand-Based Design of IKKβ Inhibitors as Anti-inflammation and Anti-cancer Agents
Current Medicinal Chemistry Targeted Enzyme Prodrug Therapies
Mini-Reviews in Medicinal Chemistry Induction of Tumour Cell Senescence: A New Strategy in Anticancer Treatment
Medicinal Chemistry Reviews - Online (Discontinued) Mode of Action of Long-Term Low-Dose Macrolide Therapy for Chronic Sinusitis in the Light of Neutrophil Recruitment
Current Drug Targets - Inflammation & Allergy Metabolic Fate of Endocannabinoids
Current Neuropharmacology Editorial :
Recent Patents on CNS Drug Discovery (Discontinued) Hypoxia Signaling and the Metastatic Phenotype
Current Molecular Medicine Molecular Link Mechanisms between Inflammation and Cancer
Current Pharmaceutical Design CNS Immune Surveillance and Neuroinflammation: Endocannabinoids Keep Control
Current Pharmaceutical Design The Quinoline Imidoselenocarbamate EI201 Blocks the AKT/mTOR Pathway and Targets Cancer Stem Cells Leading to a Strong Antitumor Activity
Current Medicinal Chemistry Epithelial Mesenchymal Transition in Cancer Progression: Prev entive Phytochemicals
Recent Patents on Anti-Cancer Drug Discovery Role of Pancreatic β-Cell Death and Cell Death-Associated Inflammation in Diabetes
Current Molecular Medicine Integrin Function and Signaling as Pharmacological Targets in Cardiovascular Diseases and in Cancer
Current Pharmaceutical Design